ncRNA name
hsa-miR-200c
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
ZEB1
Cancer name
Lung Cancer
Cancer site
Lung
Treatment type
Chemotherapy
Drug
Crizotinib
Impact of wild-type ncRNA on chemotherapy resistance
Down
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
MiR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1.
Tissue resource
lung cancer cell lines NCI-2228
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
American Type Culture Collection
Country
USA
Continent
Amercia